Sunday, December 1, 2019

Biocon Biologics to reduce the cost of human insulin and cancer drugs

The Biocon subsidiary will chart a path that ensures high volumes and lowcosts, unlike competitors, Christiane Hamacher, chief executive of Biocon Biologics told ET. https://ift.tt/2RcdZVI https://ift.tt/eA8V8J
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Sources: after five Thinking Machines staff left, investors are rattled, potentially impacting fundraising; two researchers quit via Slack during an all-hands (The Information)

The Information : Sources: after five Thinking Machines staff left, investors are rattled, potentially impacting fundraising; two researc...